Unknown

Dataset Information

0

Dual-Stage Picolinic Acid-Derived Inhibitors of Toxoplasma gondii.


ABSTRACT: Toxoplasma gondii causes a prevalent human infection for which only the acute stage has an FDA-approved therapy. To find inhibitors of both the acute stage parasites and the persistent cyst stage that causes a chronic infection, we repurposed a compound library containing known inhibitors of parasitic hexokinase, the first step in the glycolysis pathway, along with a larger collection of new structural derivatives. The focused screen of 22 compounds showed a 77% hit rate (>50% multistage inhibition) and revealed a series of aminobenzamide-linked picolinic acids with submicromolar potency against both T. gondii parasite forms. Picolinic acid 23, designed from an antiparasitic benzamidobenzoic acid class with challenging ADME properties, showed 60-fold-enhanced solubility, a moderate LogD7.4, and a 30% improvement in microsomal stability. Furthermore, isotopically labeled glucose tracing revealed that picolinic acid 23 does not function by hexokinase inhibition. Thus, we report a new probe scaffold to interrogate dual-stage inhibition of T. gondii.

SUBMITTER: Khalifa MM 

PROVIDER: S-EPMC7734631 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC2653193 | biostudies-literature
| S-EPMC4771975 | biostudies-literature
2006-05-17 | GSE4274 | GEO
| S-EPMC6017938 | biostudies-literature
| S-EPMC1500979 | biostudies-literature
| S-EPMC4230917 | biostudies-literature
| S-EPMC6200635 | biostudies-literature
| S-EPMC6290556 | biostudies-literature
| S-EPMC8273083 | biostudies-literature
| S-EPMC2932859 | biostudies-literature